Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scavenging free haemoglobin attenuates the systemic inflammatory response following surgery
2007-004856-35Phase 4Completed
- Sponsor
- Imperial College London
- Start
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of Zenalb 20% in Systemic Inflammatory Response Syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) (2 arms), sponsored by Imperial College London. Primary endpoint: Length of stay on the Intensive Care Unit. Started Mar 2008; status: completed.
02
Drugs
Zenalb 20%
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)multiple organ dysfunction syndrome (MODS)
Beyond the preview
Go deeper on 2007-004856-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004856-35.